Table 5: Risk factors for MTCT of HBV.

Case/exposed, %Univariate OR (95% CI)Adjusted OR (95% CI)

Age
 <3527/595, 4.54%1
 ≥353/56, 5.36%1.19 (0.35-4.06)
HBeAg status
 Negative8/186, 4.30%1
 Positive22/465, 4.73%1.10 (0.46-2.92)
HBV DNA before delivery
 <106 copies/mL14/264, 5.30%1
 ≥106 copies/mL16/387, 4.13%1.39 (1.17-1.64)1.21 (1.02-1.44)
ALT at baseline (U/L)
 0-4010/218, 4.59%1
 41-809/178, 5.06%1.11 (0.44-2.79)
 >8011/255, 4.31%0.94 (0.39-2.25)
Telbivudine treatment
 No29/400, 7.25%1
 Yes1/251, 0.40%0.05 (0.01-0.38)0.07 (0.01-0.55)
Gestation week
 ≥37 weeks29/620, 4.68%1
 <37 weeks1/31, 3.23%0.68 (0.09-5.16)
Mode of delivery
 Vaginal delivery22/148, 14.86%1
 Caesarean section8/503, 1.59%0.09 (0.03-0.22)0.72 (0.31-1.69)
Fetal distress
 No27/515, 5.24%1
 Yes3/136, 2.21%0.41 (0.12-1.36)
Postpartum hemorrhage
 No28/614, 4.56%1
 Yes2/37, 5.41%1.20 (0.27-5.22)
Meconium staining of the amniotic fluid
 No27/521, 5.18%1
 Yes3/130, 2.31%0.43 (0.13-1.45)
Premature rupture of membrane
 No28/585, 4.79%1
 Yes2/66, 3.03%0.62 (0.14-2.67)